ATE408699T1 - Verabreichung von nukleinsäuren und proteinen an zellen - Google Patents

Verabreichung von nukleinsäuren und proteinen an zellen

Info

Publication number
ATE408699T1
ATE408699T1 AT00909483T AT00909483T ATE408699T1 AT E408699 T1 ATE408699 T1 AT E408699T1 AT 00909483 T AT00909483 T AT 00909483T AT 00909483 T AT00909483 T AT 00909483T AT E408699 T1 ATE408699 T1 AT E408699T1
Authority
AT
Austria
Prior art keywords
proteins
cells
nucleic acids
administration
polynucleotides
Prior art date
Application number
AT00909483T
Other languages
English (en)
Inventor
Peter Francis Joseph O'hare
Nadia Michelle Normand
Original Assignee
Phogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905444.7A external-priority patent/GB9905444D0/en
Priority claimed from GBGB9930499.0A external-priority patent/GB9930499D0/en
Application filed by Phogen Ltd filed Critical Phogen Ltd
Application granted granted Critical
Publication of ATE408699T1 publication Critical patent/ATE408699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT00909483T 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen ATE408699T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905444.7A GB9905444D0 (en) 1999-03-10 1999-03-10 Delivery of sustances to cells
GBGB9930499.0A GB9930499D0 (en) 1999-12-24 1999-12-24 Delivery of substances to cells

Publications (1)

Publication Number Publication Date
ATE408699T1 true ATE408699T1 (de) 2008-10-15

Family

ID=26315249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909483T ATE408699T1 (de) 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen

Country Status (9)

Country Link
US (1) US20040171044A1 (de)
EP (1) EP1159441B8 (de)
JP (1) JP2002537828A (de)
AT (1) ATE408699T1 (de)
AU (1) AU767195B2 (de)
CA (1) CA2365625A1 (de)
DE (1) DE60040274D1 (de)
MX (1) MXPA01009073A (de)
WO (1) WO2000053722A2 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
AU2210402A (en) 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
EP1346059B1 (de) 2000-11-29 2012-05-23 PCI Biotech AS Photochemische internalisierung zur zuführung von molekülen in das zytosol
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ATE495189T1 (de) 2003-08-15 2011-01-15 Univ Florida Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
GB0321311D0 (en) * 2003-09-12 2003-10-15 Phogen Ltd Delivery of substances to cells
JP4682152B2 (ja) 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
WO2007002718A2 (en) 2005-06-27 2007-01-04 Alnylam Pharmaceuticals, Inc. Rnai modulation of hif-1 and theraputic uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体rosキナーゼ
WO2007109097A2 (en) 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Eg5遺伝子発現の抑制のための組成物および方法
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
BRPI0714875A2 (pt) 2006-07-21 2013-05-28 Silence Therapeutics Ag meios para inibir a expressço da proteÍna cinase 3
JPWO2008015841A1 (ja) * 2006-08-02 2009-12-17 梅澤 喜夫 キナーゼ阻害性融合タンパク質と医薬組成物
WO2008030986A2 (en) 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP3434259A1 (de) 2007-05-04 2019-01-30 Marina Biotech, Inc. Aminosäurelipide und verwendungen davon
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
EP3072963B1 (de) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
ES2489840T3 (es) 2008-03-05 2014-09-02 The Regents Of The University Of California Pronóstico molecular y clasificación de melanoma maligno en base a marcadores seleccionados entre la lista que consiste en RGS1, NCOA3, SPP1, PHIP
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
US8703921B2 (en) 2008-04-15 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
US20110212021A1 (en) 2008-05-30 2011-09-01 Slack Frank J Targeted oligonucleotide compositions for modifying gene expression
CA2726052A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
EP2165710A1 (de) 2008-09-19 2010-03-24 Institut Curie Tyrosinkinaserezeptor Tyro3 als therapeutisches Target bei der Behandlung eines Blasentumors
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
NZ592905A (en) 2008-10-27 2012-11-30 Baxter Int Models of thrombotic thrombocytopenic purpura and methods of use thereof
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
WO2010091878A2 (en) 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
WO2010094491A1 (en) 2009-02-18 2010-08-26 Silence Therapeutics Ag Means for inhibiting the expression of ang2
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411517A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2758189C (en) 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
EP2266550A1 (de) 2009-06-15 2010-12-29 Institut Curie Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
CA2781896C (en) 2009-12-09 2021-03-30 Nitto Denko Corporation Modulation of hsp47 expression
WO2011088435A1 (en) 2010-01-15 2011-07-21 Cornell University Methods for reducing protein levels in a cell
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
JP6033218B2 (ja) 2010-05-21 2016-11-30 ペプティメド, インコーポレイテッド がんを治療するための試薬および方法
WO2011151321A1 (en) 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
AU2011270896B9 (en) 2010-06-24 2015-05-07 Quark Pharmaceuticals, Inc. Double stranded RNA compounds to RhoA and use thereof
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
CN103328500B (zh) 2010-08-04 2018-01-26 西兹尔生物技术有限公司 用于癌症的诊断和治疗的方法和化合物
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 内部非核酸スペーサーを含む一本鎖RNAi剤
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011312504B2 (en) 2010-09-27 2016-12-22 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
AU2011308567B2 (en) 2010-10-01 2015-09-03 Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii Manipulation of stem cell function by p53 isoforms
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
SG10201508981YA (en) 2010-11-01 2015-11-27 Peptimed Inc Compositions Of A Peptide-Based System For Cell-Specific Targeting
EP2455456A1 (de) 2010-11-22 2012-05-23 Institut Curie Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EP2681314B1 (de) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen und läsionen
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
EP2557089A2 (de) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Zusammensetzungen und Verfahren zur Immunmodulation
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2802657B1 (de) 2012-01-12 2018-05-02 Quark Pharmaceuticals, Inc. Kombinationstherapie zur behandlung von gehör-und gleichgewichtsstörungen
EP2617434A1 (de) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
WO2013123996A1 (en) 2012-02-24 2013-08-29 Astrazeneca Uk Limited Novel sirna inhibitors of human icam-1
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
WO2014043289A2 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
EP2895608B1 (de) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Doppelsträngige oligonukleotidmoleküle an p53 und verfahren zur verwendung davon
HK1214301A1 (zh) 2013-02-28 2016-07-22 箭头研究公司 治療epas1相關疾病的有機組合物
WO2014135655A1 (en) 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
EP2853595A1 (de) 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1-spezifische siRNA-Moleküle
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
HRP20241236T1 (hr) 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
SG10201806064XA (en) 2014-08-27 2018-08-30 Peptimed Inc Anti-tumor compositions and methods
WO2016083624A1 (en) 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for inhibiting the expression of edn1
MX2017011422A (es) 2015-03-17 2017-11-10 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen del factor xii.
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Hif2α基因表現之組合物及方法
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3156497A1 (de) 2015-10-16 2017-04-19 Centre National de la Recherche Scientifique (C.N.R.S.) Trpv2 als biomarker und als therapeutisches target für melanome
EP3445385A4 (de) 2016-04-18 2019-11-20 The Trustees of Columbia University in the City of New York An der progression nichtalkoholischer steatohepatitis (nash) beteiligte therapeutische ziele
TWI912633B (zh) 2016-06-06 2026-01-21 美商愛羅海德製藥公司 5'-環-磷酸修飾之核苷酸
EP3269734A1 (de) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Verfahren und zusammensetzungen zur behandlung von krebs
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
CN110234326B (zh) 2017-01-30 2024-11-12 箭头药业股份有限公司 用于抑制因子xii基因表达的组合物和方法
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
EP3449978A1 (de) 2017-09-01 2019-03-06 Universite Paris Descartes Inhibitoren des arylkohlenwasserstoffrezeptors zur behandlung von weichteilsarkom und prävention von neurofibromwachstum und/oder transformation auf malignen peripheren nervenscheidentumoren
SG11201912178VA (en) 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
MX2020001912A (es) 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
CN111212909A (zh) 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US12534728B2 (en) 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
KR20210113273A (ko) 2019-01-09 2021-09-15 애로우헤드 파마슈티컬스 인코포레이티드 HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
TWI872048B (zh) 2019-02-07 2025-02-11 美商艾羅海德製藥公司 用於B型肝炎病毒感染之RNAi劑
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
TW202103698A (zh) 2019-04-18 2021-02-01 美商健生醫藥公司 用於治療b型肝炎病毒感染之組合療法
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
AU2020286462B2 (en) 2019-06-06 2026-07-02 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ
EP3808763A1 (de) 2019-10-17 2021-04-21 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verbindungen zur immunmodulation
TW202130809A (zh) 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2021175966A1 (en) 2020-03-04 2021-09-10 Ninovax Products for suppressing or reducing the expression or activity of a snorna and uses thereof in the treatment of cancer
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
KR20220158011A (ko) 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
EP4168547A1 (de) 2020-06-22 2023-04-26 Janssen Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von hepatitis-d-virusinfektionen
WO2022056273A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Lipid conjugates for the delivery of therapeutic agents
MX2023002939A (es) 2020-09-11 2023-04-11 Arrowhead Pharmaceuticals Inc Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022216920A1 (en) 2021-04-08 2022-10-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
BR112023024615A2 (pt) 2021-05-28 2024-02-20 Arrowhead Pharmaceuticals Inc Agentes de rnai para inibir expressão de mucina 5ac (muc5ac), composições dos mesmos, e métodos de uso
US11629349B2 (en) 2021-06-21 2023-04-18 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
US20230241118A1 (en) 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
JP2025522433A (ja) 2022-06-15 2025-07-15 アローヘッド ファーマシューティカルズ インコーポレイテッド スーパーオキシドジスムターゼ1(SOD1)の発現を阻害するためのRNAi剤、その組成物、及び使用の方法
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
EP4634382A1 (de) 2022-12-16 2025-10-22 Université de Strasbourg Gegen claudin-1 gerichtete rnai-basierte therapien zur behandlung und prävention von fibrotischen erkrankungen
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
EP4410825A1 (de) 2023-02-03 2024-08-07 Servizo Galego de Saude Fragmente der n-terminalen domäne von gsdmb zur behandlung von krebs
EP4684015A2 (de) 2023-03-21 2026-01-28 Arrowhead Pharmaceuticals, Inc. Rnai-mittel zur hemmung der expression des komplementfaktors b (cfb), pharmazeutische zusammensetzungen daraus und verfahren zur verwendung
EP4724100A1 (de) 2023-06-07 2026-04-15 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Kombinationstherapie mit mek-hemmern zur behandlung von krebs
IL325025A (en) 2023-06-07 2026-01-01 Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron Combination therapy with BRAF inhibitors for cancer treatment
EP4473974A1 (de) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
AU2024331015A1 (en) 2023-08-30 2026-02-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
WO2025072748A2 (en) 2023-09-29 2025-04-03 Insitro, Inc. Compositions and methods for treating nonalcoholic fatty liver disease
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
IL330211A (en) 2023-12-20 2026-08-01 Arrowhead Pharmaceuticals Inc RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), their compositions and methods of use
WO2025172510A1 (en) 2024-02-15 2025-08-21 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Compounds for treating diseases
EP4616864A1 (de) 2024-03-11 2025-09-17 Peptomyc, S.L. Verbindung zur behandlung von autoimmunerkrankungen
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
WO2025212467A1 (en) 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
US20250333742A1 (en) 2024-04-25 2025-10-30 Insitro, Inc. Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use
WO2025265013A2 (en) 2024-06-20 2025-12-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
WO2026044017A2 (en) 2024-08-21 2026-02-26 Insitro, Inc. Compositions and methods for treating nonalcoholic fatty liver disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935777A (en) * 1991-02-19 1999-08-10 University Of Florida Research Foundation, Inc. Entomopoxvirus expression system
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU705563B2 (en) * 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
WO1997024453A1 (en) * 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
AU741546B2 (en) * 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
GB9816761D0 (en) * 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins

Also Published As

Publication number Publication date
EP1159441A2 (de) 2001-12-05
JP2002537828A (ja) 2002-11-12
CA2365625A1 (en) 2000-09-14
EP1159441B1 (de) 2008-09-17
WO2000053722A2 (en) 2000-09-14
DE60040274D1 (de) 2008-10-30
EP1159441B8 (de) 2008-10-29
AU767195B2 (en) 2003-11-06
MXPA01009073A (es) 2002-05-06
US20040171044A1 (en) 2004-09-02
WO2000053722A3 (en) 2001-07-12
AU3176500A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
DE60040274D1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
DE69532532T8 (de) Chimerische papillomavirus-ahnliche partikel
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
BG101103A (bg) Теломераза при бозайници
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69637147D1 (de) Transportproteine und deren verwendungen
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
PL1966240T6 (pl) Peptydy laktoferyny użyteczne jako peptydy penetrujące komórkę
CA2413156A1 (en) Expression vectors
EP1808180A3 (de) Modifiziertes GP 100 und Verwendung dafür
WO2000006726A3 (en) Delta-related polypeptides
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004067555A3 (en) Protein and peptide delivery to mammalian cells in vitro
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
ATE202485T1 (de) Neue protein-polykation-konjugate
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
TR199802376T1 (xx) Aspergıllus Phoenıces'den Oksalat Dekarboksilaz Kodlayan Gen.
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
ATE414771T1 (de) Galaninrezeptor, nukleinsäuren,transformierte zellen und verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee